Headlines about Roka Bioscience (NASDAQ:ROKA) have been trending somewhat positive this week, according to Accern Sentiment. Accern rates the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Roka Bioscience earned a daily sentiment score of 0.02 on Accern’s scale. Accern also gave headlines about the medical research company an impact score of 45.4636445323315 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near future.

Roka Bioscience (NASDAQ:ROKA) traded down $0.09 during trading hours on Wednesday, reaching $0.94. The company’s stock had a trading volume of 124,900 shares, compared to its average volume of 375,868. Roka Bioscience has a 1 year low of $0.66 and a 1 year high of $6.20.

In other Roka Bioscience news, major shareholder Orbimed Advisors Llc sold 127,601 shares of the business’s stock in a transaction dated Wednesday, September 27th. The stock was sold at an average price of $0.98, for a total value of $125,048.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last three months, insiders sold 803,894 shares of company stock valued at $603,915. Insiders own 29.20% of the company’s stock.

WARNING: This report was originally posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://theolympiareport.com/2017/12/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-roka-bioscience-roka-share-price.html.

About Roka Bioscience

Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.

Insider Buying and Selling by Quarter for Roka Bioscience (NASDAQ:ROKA)

Receive News & Ratings for Roka Bioscience Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roka Bioscience Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.